Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET
Company Participants
Susan Pietropaolo - Managing Director
William Rice - Chairman, President and CEO
Fletcher Payne - SVP and Chief Financial Officer
Rafael Bejar - SVP and Chief Medical Officer
Conference Call Participants
Li Watsek - Cantor Fitzgerald
Soumit Roy - Jones Trading
John Newman - Canaccord Genuity
Matthew Biegler - Oppenheimer
Joe Pantginis - H.C. Wainwright
Edward Tenthoff - Piper Sandler
Operator
Good afternoon. My name is [Shondolin] (ph) and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for Third Quarter Ending September 30, 2022. At this time, all participants are in listen mode. After the speakers' remarks, there will be a question-and answer-session. [Operator Instructions] Thank you. As a reminder, this conference call is being recorded. And I would like to take this time to introduce Ms. Susan Pietropaolo. Susan, please go ahead.
Susan Pietropaolo
Thank you, Shondolin. Good afternoon, and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the third quarter ended September 20, 2022.
Earlier today, Aptose issued a press release relating to these financial results. The news release, as well as related SEC filings are accessible on Aptose's website. Joining me on today's call are Dr. William G. Rice, Chairman, President and CEO and Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer and Mr. Fletcher Payne, Senior Vice President and Chief Financial Officer.
Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of US and Canadian securities laws. Forward-looking statements reflect Aptose's current expectations regarding future events, they are not guarantees of performance and it is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievement to differ materially from those expressed.
To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent annual report on Form 10-K, at SEC and SEDAR filings. All forward-looking statements made during this call speak only as of the date they are made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law.